Enanta Pharmaceuticals
ENTA
132 hedge funds and large institutions have $225M invested in Enanta Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 45 reducing their positions, and 25 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 25
0% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 45
0.4% less ownership
Funds ownership: 96.05% → 95.65% (-0.4%)
1% less funds holding
Funds holding: 133 → 132 (-1)
47% less call options, than puts
Call options by funds: $9K | Put options by funds: $17K
49% less capital invested
Capital invested by funds: $438M → $225M (-$213M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$12.7M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$8.75M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$7.22M |
| 4 |
D.E. Shaw & Co
New York
|
+$4.97M |
| 5 |
Morgan Stanley
New York
|
+$4.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$28.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$17.2M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$4.01M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$3.22M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$2.47M |
ENTA Hedge Fund Activity: Q3 2023 in Review
132 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2023, worth a combined $225M — down 49% from $438M a quarter earlier.
Fund positioning in ENTA was balanced in Q3 2023: 25 funds opened new positions, 25 closed out, 45 added to existing stakes and 45 trimmed.
The largest buyer was Millennium Management, adding an estimated $12.7M. The largest seller was BlackRock, cutting an estimated $28.2M.
- 132 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2023, down from 133 in Q2 2023.
- Funds reported $225M of Enanta Pharmaceuticals stock for Q3 2023, down 49% quarter-over-quarter.
- 25 funds opened new Enanta Pharmaceuticals positions in Q3 2023 and 25 closed out, a net change of 0 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2023 was Millennium Management, an estimated $12.7M added.
- The largest Enanta Pharmaceuticals seller in Q3 2023 was BlackRock, an estimated $28.2M sold.
Based on aggregated 13F filings for Q3 2023.